Welcome to our dedicated page for Babcock & Wilcox Enterprises SEC filings (Ticker: BW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Babcock & Wilcox Enterprises's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Babcock & Wilcox Enterprises's regulatory disclosures and financial reporting.
Babcock & Wilcox Enterprises director Naomi Louise Boness reported compensation-related equity activity involving restricted stock units and common stock. On May 15, 2026, she exercised or converted derivative securities into 85,000 shares of common stock and received a new grant of 8,725 restricted stock units under the company’s Amended and Restated 2021 Long-Term Incentive Plan.
A portion of the vested restricted stock units representing 46,750 shares was settled in cash by the company to facilitate her tax payments, classified as a disposition to the issuer. Following these transactions, she directly owned 189,530 shares of common stock. The new restricted stock units are scheduled to vest on May 15, 2026 and May 15, 2027, or on the date of the next annual meeting in each case, whichever is earlier.
Babcock & Wilcox Enterprises, Inc. director Rebecca L. Stahl reported compensation-related equity moves. She exercised 85,000 restricted stock units into common stock and the company settled 46,750 common shares with her at $21.22 per share to facilitate tax payments. After these transactions she directly holds 184,013 common shares and 8,725 restricted stock units, with the new units vesting on May 15, 2027 or the next annual meeting, whichever is earlier.
Babcock & Wilcox Enterprises director Alan B. Howe reported several equity compensation-related transactions in company stock. On May 15, 2026, he exercised 85,000 Restricted Stock Units, which converted into an equal number of common shares at a stated value of $21.22 per share. The filing notes that a portion of the vested restricted stock units was settled in cash by Babcock & Wilcox to facilitate his tax payments, rather than through open-market sales.
Following these transactions, Howe held 165,994 shares of common stock directly, in addition to indirect holdings of 72,606 shares through the Alan & Penny Howe Trust, where he serves as trustee, and 13,000 shares in an IRA. He also received a new grant of 8,725 Restricted Stock Units under the company’s Amended and Restated 2021 Long-Term Incentive Plan, representing a contingent right to receive common stock, with vesting tied to future dates or the next annual meeting.
Babcock & Wilcox Enterprises director Dr. Homaira Akbari reported equity-based compensation activity. On May 15, 2026, she exercised 3,021 shares of common stock at $21.22 per share from restricted stock units and held 53,021 common shares afterward.
She also received 8,725 new restricted stock units tied to common stock, which vest on May 15, 2027 or the next annual meeting, and previously received 3,021 restricted stock units that vest on May 15, 2026. After these grants, she directly holds both common shares and unvested restricted stock units.
Babcock & Wilcox Enterprises director Philip D. Moeller reported compensation-related share activity involving restricted stock units. He exercised or converted 85,000 restricted stock units into common stock, and 46,750 shares were settled in cash by the company to cover tax payments under the award terms. After these transactions, he directly held 235,809 shares of common stock. Moeller also received a new grant of 8,725 restricted stock units under the Amended and Restated 2021 Long-Term Incentive Plan, which are scheduled to vest on May 15, 2027 or on the date of the next annual meeting, whichever is earlier.
Babcock & Wilcox Enterprises director Joseph A. Tato reported compensation-related equity activity. On May 15, 2026, he exercised 85,000 restricted stock units into common stock at a reported value of $21.22 per share. To facilitate tax payments, 46,750 shares were settled back to the company in cash under the award terms, rather than sold on the open market. Following these transactions, he directly held 207,338 common shares. He also received a new grant of 8,725 restricted stock units under the Amended and Restated 2021 Long-Term Incentive Plan, each representing one share of common stock, vesting by May 15, 2027 or the next annual meeting, whichever is earlier.
Babcock & Wilcox Enterprises entered into an underwriting agreement for an underwritten public offering of 10,810,811 shares of common stock at $18.50 per share. Underwriters received a 30‑day option for 1,621,621 additional shares, and closing on May 18, 2026 resulted in 12,432,432 shares issued in total, for gross proceeds of approximately $200 million before fees.
All shares are being offered by the Company under its effective shelf registration statement on Form S‑3. B&W plans to use net proceeds primarily to prepay amounts under its Credit Agreement, then reborrow to fund project capital and working capital, including AI data center power generation projects, potential acquisitions, growth initiatives, balance sheet strengthening and general corporate purposes.
Babcock & Wilcox Enterprises, Inc. is offering 10,810,811 shares of Common Stock. The prospectus supplement describes a firm-commitment underwritten offering at a public offering price of $18.50 per share with gross proceeds of approximately $200.0 million and an underwriter option to purchase up to an additional 1,621,621 shares for 30 days.
The company expects to use net proceeds to prepay amounts under its Credit Agreement (subject to lender requirements), and to reborrow for project-related capital, BrightLoop commercialization, AI data center projects, potential acquisitions, and general corporate purposes. The offering will increase shares outstanding to 147,023,312 (or 148,644,933 if the option is exercised).
Babcock & Wilcox Enterprises plans an underwritten public offering of $200 million of common stock. The company expects to grant underwriters a 30-day option to buy up to an additional 15% of the shares sold. All shares will be issued by B&W under an existing shelf registration.
The company intends to use net proceeds primarily to prepay amounts outstanding under its Credit Agreement, then reborrow to fund project-related capital and working capital, including steam turbine and boiler production, AI data center power generation projects, growth initiatives, possible acquisitions, and general corporate purposes.
Babcock & Wilcox Enterprises, Inc. is offering shares of its Common Stock in an underwritten public offering under a preliminary prospectus supplement. The offering is being underwritten on a firm commitment basis with a 30-day option for additional shares.
Proceeds are required to be applied to prepay amounts outstanding under the Company’s Credit Agreement and the Company states it would intend to reborrow such amounts to fund project-related capital, working capital, growth initiatives including AI data center projects and BrightLoop commercialization, potential acquisitions, and general corporate purposes. The Company reported 136,212,501 shares outstanding as of May 6, 2026, had approximately $58.2 million available under an at-the-market program as of May 12, 2026, and reported a pipeline of over $14.0 billion with a BrightLoop™ pipeline of more than $2.3 billion. The prospectus supplement discloses material credit metrics and contingencies, including an up to $150.0 million asset-based Credit Facility and approximately $37.9 million outstanding under the Credit Agreement as of March 31, 2026.